| Members |
targetComponentId |
| [X]Additional musculoskeletal and connective tissue disease classification terms |
Extension Namespace {1000000} (namespace concept) |
| [X]Additional neoplasm classification terms |
Extension Namespace {1000000} (namespace concept) |
| [X]Additional nervous system and sense organ disease classification terms |
Extension Namespace {1000000} (namespace concept) |
| [X]Additional perinatal disease classification terms |
Extension Namespace {1000000} (namespace concept) |
| [X]Additional pregnancy, childbirth and puerperium disease classification terms |
Extension Namespace {1000000} (namespace concept) |
| [X]Additional respiratory disease classification terms |
Extension Namespace {1000000} (namespace concept) |
| [X]Additional skin and subcutaneous tissue disease classification terms |
Extension Namespace {1000000} (namespace concept) |
| [X]Additional symptom, signs and abnormal clinical and laboratory findings classification terms |
Extension Namespace {1000000} (namespace concept) |
| [X]Adenovirus as the cause of diseases classified to other chapters |
Extension Namespace {1000000} (namespace concept) |
| [X]Adenovirus as the cause of diseases classified to other chapters |
Extension Namespace {1000000} (namespace concept) |
| [X]Adenovirus infection, unspecified |
Extension Namespace {1000000} (namespace concept) |
| [X]Adjustment and management of other implanted devices |
Extension Namespace {1000000} (namespace concept) |
| [X]Adjustment and management of unspecified implanted device |
Extension Namespace {1000000} (namespace concept) |
| [X]Adult osteomalacia, unspecified |
Extension Namespace {1000000} (namespace concept) |
| [X]Adverse drug reaction: [ENT] or [dental] or [NOS] or [unspecified topical agents] |
Extension Namespace {1000000} (namespace concept) |
| [X]Adverse reaction drug primarily affecting nervous system: [autonomic] or [CNS] |
Extension Namespace {1000000} (namespace concept) |
| [X]Adverse reaction to alkalising &/or acidifying agents |
Extension Namespace {1000000} (namespace concept) |
| [X]Adverse reaction to anti-infective: [unspecified systemic &/or antiparasitics - therapeutic] or [NOS] |
Extension Namespace {1000000} (namespace concept) |
| [X]Adverse reaction to blood substitutes: [macromolecular] or [plasma] |
Extension Namespace {1000000} (namespace concept) |
| [X]Adverse reaction to caffeine |
Extension Namespace {1000000} (namespace concept) |
| [X]Adverse reaction to enzymes: [NOS] or [NEC] |
Extension Namespace {1000000} (namespace concept) |
| [X]Adverse reaction to oral contraceptive: [therapeutic] or [unspecified] |
Extension Namespace {1000000} (namespace concept) |
| [X]Adverse reaction to other drug: [ENT] or [dental] or [NOS] or [unspecified topical agents] |
Extension Namespace {1000000} (namespace concept) |
| [X]African trypanosomiasis, unspecified |
Extension Namespace {1000000} (namespace concept) |
| [X]Agents affecting calcification causing adverse effects in therapeutic use |
Extension Namespace {1000000} (namespace concept) |
| [X]Agents affecting uric acid metabolism causing adverse effects in therapeutic use |
Extension Namespace {1000000} (namespace concept) |
| [X]Agents primarily acting on smooth and skeletal muscles and the respiratory system causing adverse effects in therapeutic use |
Extension Namespace {1000000} (namespace concept) |
| [X]Agents primarily affecting blood constituents causing adverse effects in therapeutic use |
Extension Namespace {1000000} (namespace concept) |
| [X]Agents primarily affecting bone metabolism causing adverse effects in therapeutic use |
Extension Namespace {1000000} (namespace concept) |
| [X]Agents primarily affecting nutrition causing adverse effects in therapeutic use |
Extension Namespace {1000000} (namespace concept) |
| [X]Agents primarily affecting the cardiovascular system causing adverse effects in therapeutic use |
Extension Namespace {1000000} (namespace concept) |
| [X]Agents primarily affecting the gastrointestinal system causing adverse effects in therapeutic use |
Extension Namespace {1000000} (namespace concept) |
| [X]Agents primarily affecting water-balance and mineral and uric acid metabolism causing adverse effects in therapeutic use |
Extension Namespace {1000000} (namespace concept) |
| [X]Air and space transport accidents |
Extension Namespace {1000000} (namespace concept) |
| [X]Airway disease due to other specific organic dusts |
Extension Namespace {1000000} (namespace concept) |
| [X]Alcohol deterrents causing adverse effects in therapeutic use |
Extension Namespace {1000000} (namespace concept) |
| [X]Allergic contact dermatitis due to other agents |
Extension Namespace {1000000} (namespace concept) |
| [X]Allergic contact dermatitis due to other chemical products |
Extension Namespace {1000000} (namespace concept) |
| [X]Alpha-adrenoreceptor antagonists causing adverse effects in therapeutic use, not elsewhere classified |
Extension Namespace {1000000} (namespace concept) |
| [X]Amebiasis, unspecified |
Extension Namespace {1000000} (namespace concept) |
| [X]Amebic infection of other sites |
Extension Namespace {1000000} (namespace concept) |
| [X]Aminoglycosides causing adverse effects in therapeutic use |
Extension Namespace {1000000} (namespace concept) |
| [X]Amputation of limb(s) as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure |
Extension Namespace {1000000} (namespace concept) |
| [X]Analeptics causing adverse effects in therapeutic use |
Extension Namespace {1000000} (namespace concept) |
| [X]Analgesics, antipyretics and anti-inflammatory drugs causing adverse effects in therapeutic use |
Extension Namespace {1000000} (namespace concept) |
| [X]Androgens and anabolic congeners causing adverse effects in therapeutic use |
Extension Namespace {1000000} (namespace concept) |
| [X]Anemia (nonmegaloblastic) associated with other specified nutritional deficiencies |
Extension Namespace {1000000} (namespace concept) |
| [X]Anemia in other chronic diseases classified elsewhere |
Extension Namespace {1000000} (namespace concept) |
| [X]Anesthesiology devices associated with adverse incidents |
Extension Namespace {1000000} (namespace concept) |
| [X]Anesthesiology devices associated with adverse incidents, diagnostic and monitoring devices |
Extension Namespace {1000000} (namespace concept) |
| [X]Anesthesiology devices associated with adverse incidents, miscellaneous devices, not elsewhere classified |
Extension Namespace {1000000} (namespace concept) |
| [X]Anesthesiology devices associated with adverse incidents, prosthetic and other implants, materials and accessory devices |
Extension Namespace {1000000} (namespace concept) |
| [X]Anesthesiology devices associated with adverse incidents, surgical instruments, materials and devices (including sutures) |
Extension Namespace {1000000} (namespace concept) |
| [X]Anesthesiology devices associated with adverse incidents, therapeutic (nonsurgical) and rehabilitative devices |
Extension Namespace {1000000} (namespace concept) |
| [X]Anesthetics and therapeutic gases causing adverse effects in therapeutic use |
Extension Namespace {1000000} (namespace concept) |
| [X]Aneurysm of aorta in diseases classified elsewhere |
Extension Namespace {1000000} (namespace concept) |
| [X]Aneurysm of other specified arteries |
Extension Namespace {1000000} (namespace concept) |
| [X]Angiotensin II receptor antagonists causing adverse effects in therapeutic use |
Extension Namespace {1000000} (namespace concept) |
| [X]Angiotensin-converting-enzyme inhibitors causing adverse effects in therapeutic use |
Extension Namespace {1000000} (namespace concept) |
| [X]Animal-rider or occupant of animal-drawn vehicle injured in transport accident |
Extension Namespace {1000000} (namespace concept) |
| [X]Anogenital herpes viral infection, unspecified |
Extension Namespace {1000000} (namespace concept) |
| [X]Anomalies of pupillary function in diseases classified elsewhere |
Extension Namespace {1000000} (namespace concept) |
| [X]Antenatal screening for fetal growth retardation using ultrasonics and other physical methods |
Extension Namespace {1000000} (namespace concept) |
| [X]Antenatal screening for malformations using ultrasonics and other physical methods |
Extension Namespace {1000000} (namespace concept) |
| [X]Anthrax, unspecified |
Extension Namespace {1000000} (namespace concept) |
| [X]Anti-common-cold drugs causing adverse effects in therapeutic use |
Extension Namespace {1000000} (namespace concept) |
| [X]Antiallergic and antiemetic drugs causing adverse effects in therapeutic use |
Extension Namespace {1000000} (namespace concept) |
| [X]Antiasthmatics causing adverse effects in therapeutic use, not elsewhere classified |
Extension Namespace {1000000} (namespace concept) |
| [X]Anticholinesterase agents causing adverse effects in therapeutic use |
Extension Namespace {1000000} (namespace concept) |
| [X]Anticoagulant antagonists, vitamin K and other coagulants causing adverse effects in therapeutic use |
Extension Namespace {1000000} (namespace concept) |
| [X]Anticoagulants causing adverse effects in therapeutic use |
Extension Namespace {1000000} (namespace concept) |
| [X]Antidiarrheal drugs causing adverse effects in therapeutic use |
Extension Namespace {1000000} (namespace concept) |
| [X]Antidotes and chelating agents causing adverse effects in therapeutic use, not elsewhere classified |
Extension Namespace {1000000} (namespace concept) |
| [X]Antiepileptics and antiparkinsonism drugs causing adverse effects in therapeutic use |
Extension Namespace {1000000} (namespace concept) |
| [X]Antigonadotrophins, antiestrogens, antiandrogens causing adverse effects in therapeutic use, not elsewhere classified |
Extension Namespace {1000000} (namespace concept) |
| [X]Antihelminthics causing adverse effects in therapeutic use |
Extension Namespace {1000000} (namespace concept) |
| [X]Antihyperlipidemic and antiarteriosclerotic drugs causing adverse effects in therapeutic use |
Extension Namespace {1000000} (namespace concept) |
| [X]Antimalarials and drugs acting on other blood protozoa causing adverse effects in therapeutic use |
Extension Namespace {1000000} (namespace concept) |
| [X]Antimycobacterial drugs causing adverse effects in therapeutic use |
Extension Namespace {1000000} (namespace concept) |
| [X]Antineoplastic antimetabolites causing adverse effects in therapeutic use |
Extension Namespace {1000000} (namespace concept) |
| [X]Antineoplastic natural products causing adverse effects in therapeutic use |
Extension Namespace {1000000} (namespace concept) |
| [X]Antiparkinsonism drugs causing adverse effects in therapeutic use |
Extension Namespace {1000000} (namespace concept) |
| [X]Antipruritics causing adverse effects in therapeutic use |
Extension Namespace {1000000} (namespace concept) |
| [X]Antirheumatics causing adverse effects in therapeutic use |
Extension Namespace {1000000} (namespace concept) |
| [X]Antispasticity drugs causing adverse effects in therapeutic use |
Extension Namespace {1000000} (namespace concept) |
| [X]Antithrombotic drugs [platelet-aggregation inhibitors] causing adverse effects in therapeutic use |
Extension Namespace {1000000} (namespace concept) |
| [X]Antithyroid drugs causing adverse effects in therapeutic use |
Extension Namespace {1000000} (namespace concept) |
| [X]Antitussives causing adverse effects in therapeutic use |
Extension Namespace {1000000} (namespace concept) |
| [X]Antivaricose drugs, including sclerosing agents, causing adverse effects in therapeutic use |
Extension Namespace {1000000} (namespace concept) |
| [X]Antiviral drugs causing adverse effects in therapeutic use |
Extension Namespace {1000000} (namespace concept) |
| [X]Anxiety disorder, unspecified |
Extension Namespace {1000000} (namespace concept) |
| [X]Aortic aneurysm of unspecified site, nonruptured |
Extension Namespace {1000000} (namespace concept) |
| [X]Aortic aneurysm of unspecified site, ruptured |
Extension Namespace {1000000} (namespace concept) |
| [X]Aortic valve disorders in diseases classified elsewhere |
Extension Namespace {1000000} (namespace concept) |
| [X]Aortitis in diseases classified elsewhere |
Extension Namespace {1000000} (namespace concept) |
| [X]Aplastic and other anemias |
Extension Namespace {1000000} (namespace concept) |
| [X]Apocrine sweat disorder, unspecified |
Extension Namespace {1000000} (namespace concept) |
| [X]Apocrine sweat disorder, unspecified |
Extension Namespace {1000000} (namespace concept) |
| [X]Appetite depressants [anorectics] causing adverse effects in therapeutic use |
Extension Namespace {1000000} (namespace concept) |
| [X]Arenaviral hemorrhagic fever, unspecified |
Extension Namespace {1000000} (namespace concept) |
| [X]Arthritis and polyarthritis due to other specified bacterial agents |
Extension Namespace {1000000} (namespace concept) |
FHIR